Evidence map›Paper›PMID 35646528›Full record

ArticleActa pharmaceutica Sinica. B2022

Discovery of ARF1-targeting inhibitor demethylzeylasteral as a potential agent against breast cancer.

Jie Chang, Ruirui Yang, Lifan Chen, Zisheng Fan, Jingyi Zhou, Hao Guo, Yinghui Zhang, Yadan Liu, Guizhen Zhou, Keke Zhang and 4 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Acta pharmaceutica Sinica. B, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.4field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 16 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Revisiting theNPJ drug discovery · 2025
    Article
  6. Article
  7. Membrane trafficking alterations in breast cancer progression.Frontiers in cell and developmental biology · 2024
    Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 1 country.

Jie ChangSchool of Chinese Materia Medica, Nanjing University of Chinese Medicine, Nanjing 210023, China.
Ruirui YangDrug Discovery and Design Center, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
Lifan ChenDrug Discovery and Design Center, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
Zisheng FanSchool of Chinese Materia Medica, Nanjing University of Chinese Medicine, Nanjing 210023, China.
Jingyi ZhouSchool of Chinese Materia Medica, Nanjing University of Chinese Medicine, Nanjing 210023, China.
Hao GuoDrug Discovery and Design Center, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
Yinghui ZhangDrug Discovery and Design Center, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
Yadan LiuSchool of Chinese Materia Medica, Nanjing University of Chinese Medicine, Nanjing 210023, China.
Guizhen ZhouSchool of Chinese Materia Medica, Nanjing University of Chinese Medicine, Nanjing 210023, China.
Keke ZhangSchool of Chinese Materia Medica, Nanjing University of Chinese Medicine, Nanjing 210023, China.
Kaixian ChenDrug Discovery and Design Center, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
Hualiang JiangDrug Discovery and Design Center, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
Mingyue ZhengDrug Discovery and Design Center, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
Sulin ZhangDrug Discovery and Design Center, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
Nanjing University of Chinese Medicine · CNChinese Academy of Sciences · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Image 1.

Indexed as

ADP-ribosylation factor 1Breast cancerDemethylzeylasteralVirtual screening

Identifiers

PMID35646528
PMCPMC9136604
OpenAlexW4213126087

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.